New test may predict prostate cancer treatment success
NCT ID NCT07112612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a test called minimal residual disease (MRD) can help predict how well treatment works in men with metastatic hormone-sensitive prostate cancer. Researchers will track 50 newly diagnosed patients to see how different gene patterns affect treatment response. The goal is to make treatment more personalized and precise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.